Research & KnowledgeEvent: September 2, 2026
Climb Bio shared additional data from its Phase 1 trials in Australia and China for the R&D Spotlight CLYM116 Initial Phase 1 Data.
Published
Signal category
Research & Knowledge
Quote
“additional data from Australia and China Phase 1 trials”
— Climb Bio team
Company
Climb Bio
Committed to developing better treatments for patients with immune-mediated diseases
- Industry
- Biotechnology Research
- Location
- Wellesley, US
- Company size
- 47 employees
Immune-mediated diseases impact 1:7 people and are increasing in prevalence worldwide. They occur when the immune system mistakenly attacks the tissues of the body and can result in permanent organ damage or even death. Despite advances in treatment, many patients with immune-mediated diseases suffer from poor outcomes when their disease cannot be controlled with available therapies. At Climb Bio, we believe that we can impact the pathways that cause immune-mediated diseases to give patients precious time free of disease.
Founded 2018